Patents Examined by Karlheinz R. Skowronek
  • Uses of bremelanotide in therapy for female sexual dysfunction
    Patent number: 10286034
    Abstract: Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: May 14, 2019
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, Robert Jordan, Jeffrey D. Edelson
  • Heparan sulphates
    Patent number: 10266612
    Abstract: A novel class of structurally and functionally related isolated Heparan sulphate is disclosed. The novel class of Heparan sulphates has been found to bind FGF2 and enhance the proliferation of stem cells while maintaining their pluripotency/multipotency.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: April 23, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Victor Nurcombe, Simon Cool
  • Micronized insulin and micronized insulin analogues prepared under acidic conditions, and methods of manufacturing the same under acidic conditions
    Patent number: 10258573
    Abstract: A method of preparing an inhalable insulin suitable for pulmonary delivery includes: dissolving an insulin raw material in an acidic solution to form a dissolved insulin solution; titrating the dissolved insulin solution with a buffer solution to form a suspension comprising micronized insulin particles; and stabilizing the micronized insulin particles.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 16, 2019
    Assignee: Amphastar Pharmaceuticals, Inc.
    Inventors: Jeffrey Ding, Aili Bo, Mary Ziping Luo, Jack Yongfeng Zhang
  • Protein derivatization to endow cell penetration
    Patent number: 10258695
    Abstract: Methods and reagents for enhancing cellular uptake of a cargo molecule by covalently bonding optionally-substituted fluorenyl groups to the cargo molecules, where cellular uptake includes at least partial uptake into the cytosol. Useful fluorenylation reagents include those of formula: and salts thereof where variables are as defined. Cargo molecules include peptides and proteins. Also provided are fluorenylated cargo molecules, including fluorenylated peptides and proteins.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: April 16, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ronald T. Raines, Kristen A. Andersen
  • Glycomacropeptide medical foods for nutritional management of phenylketonuria and other metabolic disorders
    Patent number: 10258074
    Abstract: Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: April 16, 2019
    Assignee: Wisonsin Alumni Research Foundation
    Inventors: Denise M. Ney, Mark R. Etzel
  • Specific modification of antibody with IgG-binding peptide
    Patent number: 10227383
    Abstract: This invention relates to an IgG-binding peptide, an IgG-binding peptide modified with a cross-linking agent, a conjugate of the IgG-binding peptide modified with a cross-linking agent and IgG, and a method for producing the conjugate, etc.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: March 12, 2019
    Assignee: Kagoshima University
    Inventor: Yuji Ito
  • Process for sorting motile particles from lesser-motile particles and apparatus suitable therefor
    Patent number: 10227562
    Abstract: Motile particles are sorted from non-motile particles in a microfluidic sorting device wherein a stream of sort fluid containing motile and non-motile particles is caused to flow adjacent a media stream in non-turbulent fashion through a sort channel, during which flow motile particles cross the interface between the adjacent flow streams, entering the media stream, and forming a motile particle-depleted sort stream. The sorting devices are easily and inexpensively fabricated and have numerous uses, in particular sorting of motile from non-motile sperm.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: March 12, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shuichi Takayama, Gary D. Smith, Timothy G. Schuster, Brenda S. Cho
  • Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
    Patent number: 10226507
    Abstract: The present invention relates to alpha-1-microglobulin for use in the treatment of a mitochondria-related disease.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: March 12, 2019
    Assignee: A1M PHARMA AB
    Inventors: Bo Åkerstrom, Magnus Gram, Lena Rosenlöf
  • Peptides of syndecan-1 for inhibiting angiogenesis
    Patent number: 10220073
    Abstract: The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: March 5, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Alan C. Rapraeger, DeannaLee M. Beauvais
  • Highly potent acid alpha-glucosidase with enhanced carbohydrates
    Patent number: 10208299
    Abstract: Recombinant human alpha glucosidase (rhGAA) composition derived from CHO cells that contains a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs, along with low amount of non-phosphorylated high mannose glycans, and low amount of terminal galactose on complex oligosaccharides. Compositions containing the rhGAA, and methods of use are described.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: February 19, 2019
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Russell Gotschall, Hung V. Do
  • Purification method for divalent cation binding proteins on anion exchange resin
    Patent number: 10202416
    Abstract: The present invention relates to a method for the purification of divalent cation binding proteins with high purity on an anion exchange resin material, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: February 12, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
  • Identifying new therapeutic agents
    Patent number: 10203323
    Abstract: Disclosed herein are methods for identifying novel drug candidates.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: February 12, 2019
    Assignee: Warp Drive Bio, Inc.
    Inventors: Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
  • GLP-1 derivatives and uses thereof
    Patent number: 10195255
    Abstract: The invention relates to a derivative of a GLP-1 analogue, optionally C-terminally extended, which derivative comprises a first and a second protracting moiety in the form of a C20 or C22 diacid radical, a bis-amino branched linker, and a first and a second further linker each comprising an OEG-like linker element; wherein these elements are interconnected via amide bonds and attached to a Lys residue of the GLP-1 analogue. The invention also relates to intermediate products in the form of novel GLP-1 analogues incorporated in the derivatives of the invention, as well pharmaceutical compositions and medical uses of the derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: February 5, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Steffen Reedtz-Runge, Per Sauerberg, Jacob Kofoed, Ingrid Pettersson, Christian W. Tornoee
  • Methods and compositions for treating hypoglycemic disorders
    Patent number: 10188702
    Abstract: This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analog thereof.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: January 29, 2019
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Doris Stoffers, Diva D. De Leon, Charles Stanley
  • Cytotoxic tubulysin compounds for conjugation
    Patent number: 10183970
    Abstract: The present invention provides one or more compounds of formula (I) for conjugation to small molecules, polymers, peptides, proteins, antibodies, antibody fragments etc.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: January 22, 2019
    Assignee: Tube Pharmaceuticals GmbH
    Inventor: Wolfgang Richter
  • Peptide particle formulation
    Patent number: 10172936
    Abstract: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which may be a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: January 8, 2019
    Assignee: FLOW PHARMA, INC.
    Inventors: Reid M. Rubsamen, David Earl Heckerman
  • Chemical induction of lactation in prepubescent non-human mammals
    Patent number: 10172912
    Abstract: The present invention describes a method of inducing lactation in non-human mammals by using a single administrations of an estrogen compound, a dopaminergic antagonist, and oxytocin. For example, the estrogen compound may be a long acting composition and is administered at least one week before the dopaminergic antagonist. However, the oxytocin administration may be given the day after the dopaminergic antagonist, after which lactation may begin immediately. Preferred compounds may comprise a non-17? estradiol and domperidone. Such an injection protocol may result in the production of commercially viable volumes of milk from prepubescent non-human mammals, such as prepubescent female non-human mammals.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: January 8, 2019
    Inventor: Jeffrey P. Erickson
  • Selective caspase inhibitors and uses thereof
    Patent number: 10167313
    Abstract: The present invention relates to compounds of Formula I, IA, II, IIA, III, or IIIA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: January 1, 2019
    Assignee: Genesis Technologies Limited
    Inventors: Jan-Eric Ahlfors, Khalid Mekouar
  • Silk protein fragment compositions and articles manufactured therefrom
    Patent number: 10166177
    Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 1, 2019
    Assignee: Silk Therapeutics, Inc.
    Inventors: Gregory H. Altman, Rebecca L. Lacouture, Rachel Lee Dow, Rachel M. Lind, Dylan S. Haas
  • Methods for promoting hair growth
    Patent number: 10166271
    Abstract: This disclosure reveals that cyclic corticotrophin releasing factor (CRF) antagonist peptides (such as astressin B, its functional fragments, and their derivatives) induce hair growth and prevent hair loss in vivo. This important discovery enables, for instance, methods of promoting hair growth, and methods of treating hair loss (such as the hair loss that occurs normally in some individuals or that is the result of a health disorder or therapeutic treatment). Exemplary cyclic CRF antagonist peptides useful in the disclosed methods are provided throughout the disclosure.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: January 1, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Million Mulugeta, Lixin Wang, Yvette Taché, Jean Rivier